Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study

NCT: NCT07197788 · ENROLLING_BY_INVITATION

NCT IDNCT07197788
StatusENROLLING_BY_INVITATION
Start Date2026-09
Completion2027-11
SponsorEndogenex, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

This study is designed to collect real-world data on the safety and performance of the Endogenex System in the cohort of participants who were originally randomized to the sham control arm of the ReCET Study.

Frequently Asked Questions

What is Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study?

Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study is a clinical trial registered under NCT07197788. Current status: ENROLLING_BY_INVITATION.

What is the status of NCT07197788?

The current status of NCT07197788 (Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study) is: ENROLLING_BY_INVITATION.

When did Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study start?

Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study started on 2026-09.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑